Toronto, A6, based Investment company Burgundy Asset Management Ltd. buys Texas Instruments Inc, Cenovus Energy Inc, Houghton Mifflin Harcourt Co, Extended Stay America Inc, Starwood Waypoint Homes, Sally Beauty Holdings Inc, Oaktree Capital Group LLC, iShares Russell 2000, Hamilton Lane Inc, sells Equifax Inc, AutoNation Inc, BWX Technologies Inc, Rockwell Collins Inc, Brookfield Infrastructure Partners LP during the 3-months ended 2017-09-30, according to the most recent filings of the investment company, Burgundy Asset Management Ltd.. As of 2017-09-30, Burgundy Asset Management Ltd. owns 103 stocks with a total value of $10.6 billion. These are the details of the buys and sells.
New Purchases: TXN, SFR, IWM, HLNE, Added Positions: CVE, HMHC, ENB, STAY, SABR, ALSN, SBH, OAK, IT, ABC, Reduced Positions: EFX, AN, PM, BAH, BAM, HTH, SU, CNI, BNS, RY, Sold Out: BWXT, COL, BIP, SERV,
For the details of Burgundy Asset Management Ltd.’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Burgundy+Asset+Management+Ltd.
Hot Value Stocks To Invest In 2018: Norwegian Cruise Line Holdings Ltd.(NCLH)
- [By Ben Levisohn]
Shares of Carnival have dropped 4.2% to $43.74 at 2:39 p.m. today, while Royal Caribbean Cruise (RCL) has tumbled 5.6% to $66.15, and Norwegian Cruise Line Holdings (NCLH) is off 4.3% at $38.63.
- [By Dan Caplinger]
The stock market once again proved its resiliency on Wednesday, bouncing back from extensive declines early in the session to recover most of its losses. The Dow Jones Industrials actually managed to post yet another record close with a modest gain, and although other major market benchmarks suffered declines, they weren’t significant. Moreover, some favorable news from certain pockets of the market helped bolster investor confidence. Toll Brothers (NYSE:TOL), Lantheus Holdings (NASDAQ:LNTH), and Norwegian Cruise Line Holdings (NASDAQ:NCLH) were among the top performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.
- [By Monica Gerson]
Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH) is expected to report its quarterly earnings at $0.37 per share on revenue of $1.10 billion.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is projected to post its quarterly earnings at $2.31 per share on revenue of $338.86 million.
- [By Teresa Rivas]
Norwegian Cruise Lines (NCLH) was up nearly 7% on Wednesday afternoon, following its fourth-quarter earnings report.
Norwegian said that it earned 56 cents a share, a penny ahead of analysts’ expectations. Revenue rose 8.5% to $1.13 billion, also squeaking past the $1.11 billion consensus estimate.
For the full year, Norwegian said it expects to earn between $3.75 and $3.85 a share, with a midpoint a penny above the $3.79 average analyst estimate. It’s first-quarter EPS guidance of 36 cents also came in ahead of the 34-cent consensus.
Instinet analyst Harry Curtiswrites that after recent missteps, it was “vital” for Norwegian’s forecast to meet expectations but not seem too optimistic, a balancing act he believes the company achieved.
He reiterated a Buy rating and $52 price target on the stock:
NCLHs 2017 EPS outlook ($3.75 to $3.85) brackets our forecast ($3.75) and the Streets ($3.79). However, we believe there could be upside to that range, given the positive booking and pricing trends so far this year. We remain positive on the shares of NCLH, which we believe should continue to outperform through 2017.
Norwegian was recently up 6.8% to $51.49.
Hot Value Stocks To Invest In 2018: Tele Celular Sul Participacoes S.A.(TSU)
- [By Lisa Levin]
In trading on Monday, telecommunications services shares fell 0.45 percent. Meanwhile, top losers in the sector included Shenandoah Telecommunications Company (NASDAQ: SHEN), down 3 percent, and TIM Participacoes SA (ADR) (NYSE: TSU) down 2 percent.
Hot Value Stocks To Invest In 2018: CytRx Corporation(CYTR)
- [By Roberto Pedone]
Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.
If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.
Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.